Your browser doesn't support javascript.
loading
Interferon-induced IFIT5 promotes epithelial-to-mesenchymal transition leading to renal cancer invasion.
Lo, U-Ging; Bao, Jiming; Cen, Junjie; Yeh, Hsin-Chih; Luo, Junhang; Tan, Wanlong; Hsieh, Jer-Tsong.
Afiliação
  • Lo UG; Department of Urology, University of Texas Southwestern Medical Center Dallas, TX 75390, USA.
  • Bao J; Department of Urology, Nanfang Hospital, Southern Medical University Guangzhou 510515, Republic of China.
  • Cen J; Department of Urology, The First Affiliated Hospital, Sun Yat-sen University Guangzhou 510080, Republic of China.
  • Yeh HC; Department of Urology, University of Texas Southwestern Medical Center Dallas, TX 75390, USA.
  • Luo J; Department of Urology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital Taiwan, Republic of China.
  • Tan W; Department of Urology, The First Affiliated Hospital, Sun Yat-sen University Guangzhou 510080, Republic of China.
  • Hsieh JT; Department of Urology, Nanfang Hospital, Southern Medical University Guangzhou 510515, Republic of China.
Am J Clin Exp Urol ; 7(1): 31-45, 2019.
Article em En | MEDLINE | ID: mdl-30906803
ABSTRACT
Interferon is known as a pleiotropic factor in innate immunity, cancer immunity and therapy. Despite an objective short-term response of interferon (IFN) therapy in renal cell carcinoma (RCC) patients, the potential adverse effect of IFN on RCC cells is not fully understood. In this study, we demonstrate that IFNs can enhance RCC invasion via a new mechanism of IFIT5-mediated tumor suppressor microRNA (miRNA) degradation resulted in the elevation of Slug and ZEB1 and epithelial-to-mesenchymal transition (EMT). Clinically, a significant upregulation of IFNγ signaling pathway (such as IFNGR1, IFNGR2, STAT1 and STAT2) is observed in RCC patients with metastatic disease. Overall, this study provides a new mechanism of action of IFN-elicited canonical pathway in regulating suppressor miRNAs. Most importantly, it highlights the potential pro-metastatic effect of IFNs, which could undermine the clinical applicability of IFNs for treating RCC patients.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Am J Clin Exp Urol Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Am J Clin Exp Urol Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos